Statements (91)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Roche acquisition in 2002
|
| gptkbp:acquisition_year |
gptkb:2002
|
| gptkbp:awards |
received multiple industry awards
|
| gptkbp:biologics |
develops biologic therapies
|
| gptkbp:business_model |
committed to ethical business practices
|
| gptkbp:ceo |
gptkb:Takahiro_Kato
Takahiro Kiyoshi |
| gptkbp:clinical_trial |
global
ongoing conducts clinical research studies conducts clinical trials globally conducts Phase I to Phase III trials has a robust clinical development pipeline |
| gptkbp:collaboration |
academic institutions
collaborates with academic institutions collaborates with Roche on drug development |
| gptkbp:collaborations |
engages in research collaborations with universities.
|
| gptkbp:community_engagement |
involved in community engagement initiatives
|
| gptkbp:conducts_research_on |
gptkb:Dr._Masahiro_Kato
|
| gptkbp:cultural_diversity |
promotes diversity and inclusion in the workplace
|
| gptkbp:employees |
over 5,000
approximately 6,000 approximately 7,000 |
| gptkbp:financial_performance |
strong financial performance in recent years
|
| gptkbp:founded |
gptkb:1982
1925 1943 |
| gptkbp:founder |
gptkb:Kiyoshi_Chugai
|
| gptkbp:global_presence |
operates in multiple countries
|
| gptkbp:governance |
adheres to high standards of corporate governance
|
| gptkbp:headcount |
approximately 7,000 employees globally
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| gptkbp:healthcare |
engages with healthcare professionals
focuses on improving patient access to medications |
| https://www.w3.org/2000/01/rdf-schema#label |
Chugai Pharmaceutical
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
invests in innovative research
|
| gptkbp:instruction_set |
multiple drug candidates in development
|
| gptkbp:invention |
numerous
holds numerous patents in biotechnology |
| gptkbp:investment |
invests in cutting-edge technologies
|
| gptkbp:leadership |
holds a leading position in the Japanese market
led by a team of experienced executives |
| gptkbp:market |
gptkb:Japan
international markets |
| gptkbp:market_cap |
¥1 trillion (2021)
|
| gptkbp:marketing_strategy |
develops strategic marketing initiatives
|
| gptkbp:parent_company |
gptkb:Roche
|
| gptkbp:partnership |
gptkb:Genentech
gptkb:Roche collaboration with Genentech |
| gptkbp:partnerships |
forms strategic partnerships
|
| gptkbp:product_quality |
emphasizes quality control in manufacturing
|
| gptkbp:products |
gptkb:Atezolizumab
gptkb:Rituximab gptkb:Trastuzumab biopharmaceuticals |
| gptkbp:regulatory_compliance |
manages regulatory affairs globally
|
| gptkbp:research_and_development |
significant investment in R& D
|
| gptkbp:research_areas |
rare diseases
autoimmune diseases cardiovascular diseases infectious diseases metabolic diseases |
| gptkbp:research_focus |
neurology
oncology immunology focus on high unmet medical needs |
| gptkbp:revenue |
¥1.1 trillion (2020)
¥500 billion (2020) |
| gptkbp:safety |
prioritizes patient safety in all operations
|
| gptkbp:small_molecule_drugs |
develops small molecule drugs
|
| gptkbp:social_responsibility |
engages in CSR activities
|
| gptkbp:specializes_in |
biopharmaceuticals
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Chugai_Pharma_Europe
gptkb:Chugai_Pharma_USA |
| gptkbp:supply_chain |
maintains a robust supply chain
|
| gptkbp:sustainability |
focuses on sustainable practices
|
| gptkbp:sustainability_initiatives |
gptkb:administration
social responsibility environmental responsibility |
| gptkbp:therapeutic_products |
offers a range of therapeutic products
|
| gptkbp:training |
provides extensive employee training programs
|
| gptkbp:treatment |
aims to improve clinical outcomes for patients
|
| gptkbp:website |
www.chugai-pharm.co.jp
|
| gptkbp:bfsParent |
gptkb:Vernalis_Therapeutics
gptkb:Daiichi_Sankyo,_Inc. gptkb:Chugai_Pharma_USA |
| gptkbp:bfsLayer |
6
|